Nerandomilast May Slow Down Progressive Pulmonary Fibrosis
TOPLINE: In a phase 3 study, nerandomilast administered at 18 mg or 9 mg twice daily slowed the progression of pulmonary fibrosis in adults with progressive pulmonary fibrosis. METHODOLOGY: In a previous study, nerandomilast, a preferential inhibitor of phosphodiesterase 4B, was found to slow the progression of idiopathic pulmonary fibrosis. The present phase 3, randomized …
Nerandomilast May Slow Down Progressive Pulmonary Fibrosis Read More »